Ligand Pharmaceuticals Incorporated (LGND)

Ligand Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	63.62	22.95	45.01	19.52	47.62	71.54
Short-Term Investments	156.02	147.36	166.86	321.59	363.57	998.32
Cash & Short-Term Investments	219.64	170.31	211.87	341.11	411.19	1,070
Cash Growth	15.30%	-19.62%	-37.89%	-17.04%	-61.57%	38.26%
Accounts Receivable	40.92	32.92	30.42	85.45	56.85	30.39
Other Receivables	7.81	6.4	4.61	6.19	2.22	11.36
Receivables	48.73	39.31	35.04	91.65	59.06	41.75
Inventory	16.74	23.97	13.29	27.33	26.49	7.3
Prepaid Expenses	-	1.18	1.13	-	-	-
Restricted Cash	-	-	-	-	0.34	0.73
Other Current Assets	24.27	2.66	2.27	4.67	3.48	4
Total Current Assets	309.39	237.43	263.6	464.75	500.56	1,124
Property, Plant & Equipment	25.19	25.06	27.49	32.6	37.17	17.62
Long-Term Investments	13.15	48.32	3	-	-	-
Goodwill	105.25	103.37	105.67	105.67	189.66	95.23
Other Intangible Assets	274.91	366.9	352.64	386.8	606.31	230.54
Long-Term Deferred Tax Assets	0.08	0.21	8.53	35.73	24.32	25.61
Other Long-Term Assets	27.65	5.92	1.74	272.03	4.27	2.27
Total Assets	954.87	787.22	762.67	1,298	1,362	1,495
Accounts Payable	4.69	2.43	5.31	8.4	3.78	2.42
Accrued Expenses	13.22	10.09	13.3	12.4	15.61	5.55
Current Portion of Long-Term Debt	-	-	76.7	-	-	-
Current Portion of Leases	1.09	0.41	0.72	1.41	8.48	1.26
Current Unearned Revenue	1.15	1.22	0.36	0.65	29.44	2.14
Other Current Liabilities	2.51	2.63	2.43	18.8	42.8	5.63
Total Current Liabilities	24.77	16.78	98.81	41.67	100.11	17
Long-Term Debt	-	-	-	320.72	442.29	638.96
Long-Term Leases	6.27	5.77	10.34	2.31	5.76	10.04
Long-Term Unearned Revenue	17.83	15.14	0.04	-	-	-
Long-Term Deferred Tax Liabilities	46.4	31.62	30.62	30.86	64.6	32.94
Other Long-Term Liabilities	18.41	16.98	25.37	80.88	40	28.74
Total Liabilities	113.69	86.3	165.18	476.43	652.76	727.68
Common Stock	0.02	0.02	0.02	0.02	0.02	0.02
Additional Paid-In Capital	309.34	198.7	147.59	372.97	318.36	367.33
Retained Earnings	530.07	503.02	450.86	449.09	391.95	400.11
Comprehensive Income & Other	1.75	-0.82	-0.98	-0.92	-0.8	-0.22
Total Common Equity	841.18	700.91	597.49	821.16	709.53	767.23
Shareholders' Equity	841.18	700.91	597.49	821.16	709.53	767.23
Total Liabilities & Equity	954.87	787.22	762.67	1,298	1,362	1,495
Total Debt	7.36	6.18	87.75	324.44	456.53	650.26
Net Cash (Debt)	212.29	164.13	124.12	16.66	-45.34	419.61
Net Cash Growth	15.26%	32.23%	644.83%	-	-	205.10%
Net Cash Per Share	11.57	9.24	7.36	0.97	-2.69	21.24
Filing Date Shares Outstanding	18.9	17.71	17.08	16.85	16.61	16.51
Total Common Shares Outstanding	18.76	17.56	16.95	16.77	16.08	16.82
Working Capital	284.62	220.65	164.79	423.09	400.45	1,107
Book Value Per Share	44.84	39.92	35.25	48.97	44.13	45.61
Tangible Book Value	461.02	230.65	139.18	328.69	-86.45	441.47
Tangible Book Value Per Share	24.57	13.14	8.21	19.60	-5.38	26.24
Machinery	-	9.98	15.16	14.34	15.72	7.31
Leasehold Improvements	-	12.28	7.45	5.27	3.52	2.73

Source: S&P Capital IQ. Standard template. Financial Sources.